Boosting treatment efficacy of breast and gastric cancer
AC101 is a monoclonal therapeutic antibody for the treatment of HER2 expressing breast and gastric cancer
AC101 is a monoclonal antibody that binds to a unique site of the HER2 disease protein
(compared to commercialized antibodies such as Herceptin and Perjeta). When used in
combination with Herceptin, AC101 boasts better anticancer efficacy in breast / gastric
cancer animal than the traditional Herceptin & Perjeta combination. AC101 is currently
undergoing clinical trials after being transferred to Shanghai Henlius Biotech.
Anticancer Efficacy in vivo
Decisive elimination and suppression of gastric cancer cells
AbClon Inc. #1401 285, Digital-ro, Guro-gu, Seoul, Republic of Korea
T. +82-2109-1294 F. +82-2109-1296 E. abclon@abclon.com
